Media headlines about Orexigen Therapeutics (NASDAQ:OREX) have trended somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Orexigen Therapeutics earned a news impact score of 0.10 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.0811677889056 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

Separately, Zacks Investment Research upgraded Orexigen Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th.

Shares of Orexigen Therapeutics (OREX) remained flat at $$1.14 during midday trading on Wednesday. The company had a trading volume of 124,464 shares, compared to its average volume of 261,226. The company has a quick ratio of 1.71, a current ratio of 2.00 and a debt-to-equity ratio of -2.75. The firm has a market capitalization of $17.59, a price-to-earnings ratio of -0.12 and a beta of 2.31. Orexigen Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $5.70.

Orexigen Therapeutics (NASDAQ:OREX) last issued its quarterly earnings data on Monday, November 13th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.13) by $0.78. The business had revenue of $18.90 million during the quarter, compared to the consensus estimate of $24.20 million. Orexigen Therapeutics had a negative return on equity of 824.15% and a negative net margin of 192.65%. The business’s revenue was up 170.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.12 earnings per share. analysts forecast that Orexigen Therapeutics will post -10.08 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at

Orexigen Therapeutics Company Profile

Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.

Insider Buying and Selling by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

Receive News & Ratings for Orexigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics and related companies with's FREE daily email newsletter.